AstraZeneca said on Monday its experimental treatment tozorakimab met the main goal in a late-stage trial, reflecting a sharp reduction in moderate-to-severe flare-ups of chronic obstructive pulmonary disease (COPD).
AstraZeneca's tozorakimab delivers sharp reduction in COPD flare‑ups
.jpg?20260420')
An Astra Zeneca logo is pictured in Brussels, Belgium. Image credit: Reuters
&uuid=(email))